Isomorphic Labs
Isomorphic Labs is an AI-first drug design and development company that transforms drug discovery by using machine learning to design and evaluate new medicines. It builds on research from DeepMind, including the AlphaFold system, which is used to predict protein structures and understand how biological molecules interact. The company develops AI models that simulate biological processes and support the design of drug candidates across multiple disease areas. Its platform integrates predictive and generative AI systems to explore chemical space, identify therapeutic targets, and propose new molecular structures with potential medical applications. It collaborates with pharmaceutical companies on research programs in areas such as oncology and immunology, with the aim of accelerating early-stage drug discovery and improving candidate selection. The organization also develops internal pipelines of AI-designed drug candidates and is progressing toward clinical testing of its first programs. Its work combines computational biology, medicinal chemistry, and machine learning to support end-to-end drug design workflows, from target identification to preclinical evaluation.
Founded by Demis Hassabis (Founder & CEO)
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series B | May 12, 2026 | $2.1B | — |
| Series A | Mar 31, 2025 | $600M | — |
| Series A | Mar 1, 2025 | — | $1.8B |
| Seed | Apr 10, 2022 | $1.7M | — |
- TCThrive Capital
- GVGoogle Ventures
- ALAlphabet
- CACapitalG
- GOGoogle
- THTemasek Holdings
- MGMGX
- SASovereign AI Fund
- TCThrive Capital Partners
| Kind | Implied valuation | Price / share | Date |
|---|---|---|---|
| $48.5B | $6.12 | Oct 16, 2026 |
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of Oct 16, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.
